<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129362">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01811576</url>
  </required_header>
  <id_info>
    <org_study_id>TV1106-GHD-201</org_study_id>
    <nct_id>NCT01811576</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency</brief_title>
  <official_title>A 64-Week (12-week Core Phase and 52-week Safety Extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Germany: Ministry of Health</authority>
    <authority>Hungary: Ministry of Health, Social and Family Affairs</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Serbia and Montenegro: Agency for Drugs and Medicinal Devices</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>Slovenia: Ministry of Health</authority>
    <authority>Sweden: The National Board of Health and Welfare</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the clinical effect of TV-1106.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Insulin-like growth factor I (IGF-I) concentration change from baseline</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients treated with TV1106 who return to pre-treatment IGF-1 SDS</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Parameters</measure>
    <time_frame>78 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The safety of TV-1106 will be assessed throughout the study by evaluating adverse events,concomitant medication usage, physical examinations including urinalysis and body weight, vital sign measurements, clinical laboratory test results and hormone levels, electrocardiograms (ECGs), and immunogenicity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>TV-1106</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titration dose levels of TV-1106</description>
  </arm_group>
  <arm_group>
    <arm_group_label>recombinant human growth hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily subcutaneous dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TV-1106</intervention_name>
    <arm_group_label>TV-1106</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human growth hormone</intervention_name>
    <description>Subcutaneous once daily</description>
    <arm_group_label>recombinant human growth hormone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient agrees to provide written informed consent and to comply with the study
             protocol after reading the informed consent and discussing the study with the
             investigator.

          -  Males and females between 23 and 65 years of age must have a confirmed diagnosis of
             adult GHD, either adult onset (AO) GHD due to hypothalamic-pituitary disease or
             childhood onset (CO) GHD that is either idiopathic or due to hypothalamic-pituitary
             disease or due to genetic causes.

          -  Diagnosis of GH deficiency must be confirmed by documented (medical records)
             diagnostic testing.

          -  Patients should have been treated with a stable dose of daily rhGH for at least 3
             months prior to screening.

          -  Other criteria apply.

        Exclusion Criteria:

          -  Patients with history or clinical evidence of active or chronic diseases that could
             confound results of the study or put the subject at undue risk as determined by the
             investigator.

          -  Patients with known active malignancy

          -  Patients with history of malignancy other than intracranial tumor causing GHD
             (excluding surgically cured basal cell or squamous cell cancer of the skin with
             documented 6 month remission)

          -  Patients with evidence of pituitary adenoma or other intracranial tumor within 12
             months of enrollment, which is on day 0 (baseline, Visit 3)

          -  Patients without magnetic resonance imaging (MRI) or computerized tomography (CT)
             data to document tumor stability within the 12 months prior to enrollment, which is
             on day 0 (baseline, Visit 3)

          -  Presence of Prader-Willi syndrome, Turner's syndrome, untreated adrenal
             insufficiency, active acromegaly in the past 5 years, or active Cushing's syndrome in
             the past 1 year.

          -  Other criteria apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Teva Investigational Site 10564</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54069</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54052</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54051</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54053</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32239</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32238</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32237</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 63044</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 63045</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51055</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51056</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51060</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51061</name>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51059</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51057</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 51058</name>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80033</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80032</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80034</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 61029</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 62017</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 62022</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 62016</name>
      <address>
        <city>Lubochna</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 64016</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 22, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth hormone deficiency</keyword>
  <keyword>Insulin-like growth factor I (IGF-I)</keyword>
  <keyword>TV-1106</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
